Skip to main content

Table 4 Quantitative RT-PCR validation in non small cell lung carcinoma samples

From: A dedicated microarray for in-depth analysis of pre-mRNA splicing events: application to the study of genes involved in the response to targeted anticancer therapies

A

           

Sample

1

2

3

4

5

6

7

8

9

10

 

SRSF2 Protein Score

270

270

240

180

160

140

120

100

60

n/a

 

Phospho-SRSF2 Protein Score

270

270

270

100

100

90

60

100

40

n/a

 

B

  
 

Non small cell lung carcinoma vs . normal lung tissue

 

Gene

Calculation

Transcript

1

2

3

4

5

6

7

8

9

10

Observed Transcript Regulation

HER1/EGFR

Relative expression

Last exon = e17

n/a

n/a

n/a

n/a

7.17

n/a

n/a

16.15

2.52

n/a

Not expressed or over-expressed

  

Last exon = e18

2.69

n/a

1.86

2.27

5.13

6.86

2.23

15.16

3.01

66.18

Over-expressed

  

Last exon > e20

0.15

0.29

0.20

6.71

6.99

21.45

0.10

5.39

2.46

n/a

Over-expressed or under-expressed

AKT3

Fold-change

e7+ e8- vs. e7+ e8+

0.84

1.46

1.16

1.37

1.08

1.76

1.29

1.47

1.47

2.28

Over-expression or no regulation

  

e7- e8+ vs. e7+ e8+

n/a

1.33

n/a

1.35

n/a

n/a

n/a

0.38

n/a

n/a

Low expression of e7- e8+

  

e7- e8- vs. e7+ e8+

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

No expression of e7- e8-

HIF1A

Fold-change

e9+ e10- vs. e9+ e10+

0.63

0.54

1.63

1.40

0.79

1.77

0.87

1.22

1.20

1.15

Depending on biopsy samples

  

e9- e10+ vs. e9+ e10+

1.87

n/a

n/a

1.06

n/a

n/a

n/a

n/a

1.14

1.77

Depending on biopsy samples

  

e9- e10- vs. e9+ e10+

0.57

0.73

1.55

1.49

0.84

1.88

0.79

1.99

0.76

1.01

Depending on biopsy samples

VEGFA

Fold-change

Last exon = e4 vs. Last exon > e5

1.33

1.21

1.54

1.92

0.84

2.22

10.37

2.73

1.21

1.09

Over-expression or no regulation

VEGFA

Fold-change

Alternative vs. constitutive donor e6

3.50

3.33

5.25

3.99

n/a

n/a

19.22

14.29

n/a

45.68

Over-expression

  1. The regulation of the 10 selected deregulated custom probe sets was analysed by quantitative RT-PCR in 10 non small cell lung carcinoma – normal sample pairs (patients numbered from 1 to 10). SRSF2 protein expression levels in biopsy samples were analysed by immunohistochemistry in a previous study. A score (0–300) was established for SRSF2 and phosphorylated SRSF2 (P-SRSF2). Patients with scores ≥ 150 and > 175 were those over-expressing SRSF2 and P-SRSF2 proteins respectively, as compared to normal lung tissues. Patients in bold characters over-expressed both proteins. n/a: not available.
  2. Relative mRNA levels were normalised to that of beta-2-microglobulin or a fold-change was calculated comparing to a reference event. The cut-off value was equal to 1.40. n/a: not available. Patients in bold characters over-expressed both SRSF2 and phospho-SRSF2 proteins (see Table 4A).
Back to article page

Molecular Cancer

ISSN: 1476-4598